Universität zu Köln

Schultink, A. H. M. de Vries, Suleiman, A. A., Schellens, J. H. M., Beijnen, J. H. and Huitema, A. D. R. (2016). Pharmacodynamic modeling of adverse effects of anti-cancer drug treatment. Eur. J. Clin. Pharmacol., 72 (6). S. 645 - 654. HEIDELBERG: SPRINGER HEIDELBERG. ISSN 1432-1041

Full text not available from this repository.

Abstract

Adverse effects related to anti-cancer drug treatment influence patient's quality of life, have an impact on the realized dosing regimen, and can hamper response to treatment. Quantitative models that relate drug exposure to the dynamics of adverse effects have been developed and proven to be very instrumental to optimize dosing schedules. The aims of this review were (i) to provide a perspective of how adverse effects of anti-cancer drugs are modeled and (ii) to report several model structures of adverse effect models that describe relationships between drug concentrations and toxicities. Various quantitative pharmacodynamic models that model adverse effects of anti-cancer drug treatment were reviewed. Quantitative models describing relationships between drug exposure and myelosuppression, cardiotoxicity, and graded adverse effects like fatigue, hand-foot syndrome (HFS), rash, and diarrhea have been presented for different anti-cancer agents, including their clinical applicability. Mathematical modeling of adverse effects proved to be a helpful tool to improve clinical management and support decision-making (especially in establishment of the optimal dosing regimen) in drug development. The reported models can be used as templates for modeling a variety of anti-cancer-induced adverse effects to further optimize therapy.

Item Type:	Journal Article
Creators:	Creators Email ORCID ORCID Put Code Schultink, A. H. M. de Vries UNSPECIFIED UNSPECIFIED UNSPECIFIED Suleiman, A. A. UNSPECIFIED UNSPECIFIED UNSPECIFIED Schellens, J. H. M. UNSPECIFIED UNSPECIFIED UNSPECIFIED Beijnen, J. H. UNSPECIFIED UNSPECIFIED UNSPECIFIED Huitema, A. D. R. UNSPECIFIED UNSPECIFIED UNSPECIFIED
URN:	urn:nbn:de:hbz:38-274166
DOI:	10.1007/s00228-016-2030-4
Journal or Publication Title:	Eur. J. Clin. Pharmacol.
Volume:	72
Number:	6
Page Range:	S. 645 - 654
Date:	2016
Publisher:	SPRINGER HEIDELBERG
Place of Publication:	HEIDELBERG
ISSN:	1432-1041
Language:	English
Faculty:	Unspecified
Divisions:	Unspecified
Subjects:	no entry
Uncontrolled Keywords:	Keywords Language TRASTUZUMAB-ASSOCIATED CARDIOTOXICITY; CHEMOTHERAPY-INDUCED NEUTROPENIA; ADVANCED SOLID TUMORS; PHASE-I; INDUCED THROMBOCYTOPENIA; CANCER-PATIENTS; BREAST-CANCER; TIME-COURSE; POPULATION; MYELOSUPPRESSION Multiple languages Pharmacology & Pharmacy Multiple languages
Refereed:	Yes
URI:	http://kups.ub.uni-koeln.de/id/eprint/27416